SOHO 2018 | Venetoclax combinations effective in elderly AML

Marina Konopleva

While venetoclax is widely used in chronic lymphocytic leukemia (CLL) to good effect, previous studies have suggested that the drug does not yield such good results in acute myeloid leukemia (AML). In this video, recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Marina Konopleva, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, discusses several recent trials (NCT02203773, NCT02287233) that explored the efficacy of venetoclax in combination with hypomethylating agents or low-dose cytarabine in elderly, untreated AML patients. The results were positive, and Prof. Konopleva finishes by suggesting future implications for these data.

Share this video